-

NeoGenomics to Participate in the Piper Sandler 36th Annual Healthcare Conference

FT. MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics, Inc. (NASDAQ: NEO), a leading oncology testing services company, will attend the Piper Sandler 36th Annual Healthcare Conference. Members of the management team will participate in an in-person fireside chat on Thursday, Dec. 5, 2024, at 9:30 a.m. ET in New York City.

The presentation will be webcast live and accessible online via this link. A replay will be available on the Investor Relations section of the Company’s website at ir.neogenomics.com.

About NeoGenomics, Inc.

NeoGenomics, Inc. specializes in cancer genetics testing and information services, providing one of the most comprehensive oncology-focused testing menus for physicians to help them diagnose and treat cancer. The Company’s Advanced Diagnostic Division also serves pharmaceutical clients in clinical trials and drug development.

Headquartered in Fort Myers, FL, NeoGenomics operates CAP accredited and CLIA certified laboratories for full-service sample processing in Fort Myers, Florida; Aliso Viejo and San Diego, California; Research Triangle Park, North Carolina; and Houston, Texas; and a CAP accredited full-service, sample-processing laboratory in Cambridge, United Kingdom. NeoGenomics also has several, small, non-processing laboratory locations across the United States for providing analysis services. NeoGenomics serves the needs of pathologists, oncologists, academic centers, hospital systems, pharmaceutical firms, integrated service delivery networks, and managed care organizations throughout the United States, and pharmaceutical firms in Europe and Asia.

Contacts

Investor Contact
Kendra Sweeney
kendra.sweeney@neogenomics.com

Media Contact
Andrea Sampson
asampson@sampsonprgroup.com

NeoGenomics, Inc.

NASDAQ:NEO

Release Summary
NeoGenomics will participate in a fireside chat at the Piper Sandler 36th Annual Healthcare Conference in New York City.
Release Versions

Contacts

Investor Contact
Kendra Sweeney
kendra.sweeney@neogenomics.com

Media Contact
Andrea Sampson
asampson@sampsonprgroup.com

Social Media Profiles
More News From NeoGenomics, Inc.

NeoGenomics Launches FDA-Approved PTEN IHC Companion Diagnostic for Prostate Cancer

FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics launched PTEN IHC CDx, the first IHC companion diagnostic test approved by the U.S. FDA for patients with prostate adenocarcinoma....

NeoGenomics to Report Second Quarter 2026 Financial Results on July 28, 2026

FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics will report its second quarter 2026 financial results after the close of U.S. financial markets on Tuesday, July 28, 2026....

NeoGenomics Appoints Carolyn Starrett to its Board of Directors

FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics announced the appointment of Carolyn Starrett to its Board of Directors....
Back to Newsroom